Cargando…
Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations
Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous system tumour in adults. It has extremely poor prognosis since the current standard of care, comprising of gross total resection and temozolomide (TMZ) chemoradiotherapy, prolongs survival, but does not provide a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060812/ https://www.ncbi.nlm.nih.gov/pubmed/35509452 http://dx.doi.org/10.2147/OTT.S215997 |
_version_ | 1784698587745091584 |
---|---|
author | Niedbała, Marcin Malarz, Katarzyna Sharma, Gitanjali Kramer-Marek, Gabriela Kaspera, Wojciech |
author_facet | Niedbała, Marcin Malarz, Katarzyna Sharma, Gitanjali Kramer-Marek, Gabriela Kaspera, Wojciech |
author_sort | Niedbała, Marcin |
collection | PubMed |
description | Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous system tumour in adults. It has extremely poor prognosis since the current standard of care, comprising of gross total resection and temozolomide (TMZ) chemoradiotherapy, prolongs survival, but does not provide a durable response. To a certain extent, this is due to GBM’s heterogeneous, hostile and cold tumour microenvironment (TME) and the unique ability of GBM to overcome the host’s immune responses. Therefore, there is an urgent need to develop more effective therapeutic approaches. This review provides critical insights from completed and ongoing clinical studies investigating novel immunotherapy strategies for GBM patients, ranging from the use of immune checkpoint inhibitors in different settings of GBM treatment to novel combinatorial therapies. In particular, we discuss how treatment regimens based on single antigen peptide vaccines evolved into fully personalised, polyvalent cell-based vaccines, CAR-T cell, and viral or gene therapies. Furthermore, the results of the most influential clinical trials and a selection of innovative preclinical studies aimed at activating the immunologically cold GBM microenvironment are reviewed. |
format | Online Article Text |
id | pubmed-9060812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-90608122022-05-03 Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations Niedbała, Marcin Malarz, Katarzyna Sharma, Gitanjali Kramer-Marek, Gabriela Kaspera, Wojciech Onco Targets Ther Review Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous system tumour in adults. It has extremely poor prognosis since the current standard of care, comprising of gross total resection and temozolomide (TMZ) chemoradiotherapy, prolongs survival, but does not provide a durable response. To a certain extent, this is due to GBM’s heterogeneous, hostile and cold tumour microenvironment (TME) and the unique ability of GBM to overcome the host’s immune responses. Therefore, there is an urgent need to develop more effective therapeutic approaches. This review provides critical insights from completed and ongoing clinical studies investigating novel immunotherapy strategies for GBM patients, ranging from the use of immune checkpoint inhibitors in different settings of GBM treatment to novel combinatorial therapies. In particular, we discuss how treatment regimens based on single antigen peptide vaccines evolved into fully personalised, polyvalent cell-based vaccines, CAR-T cell, and viral or gene therapies. Furthermore, the results of the most influential clinical trials and a selection of innovative preclinical studies aimed at activating the immunologically cold GBM microenvironment are reviewed. Dove 2022-04-28 /pmc/articles/PMC9060812/ /pubmed/35509452 http://dx.doi.org/10.2147/OTT.S215997 Text en © 2022 Niedbała et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Niedbała, Marcin Malarz, Katarzyna Sharma, Gitanjali Kramer-Marek, Gabriela Kaspera, Wojciech Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations |
title | Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations |
title_full | Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations |
title_fullStr | Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations |
title_full_unstemmed | Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations |
title_short | Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations |
title_sort | glioblastoma: pitfalls and opportunities of immunotherapeutic combinations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060812/ https://www.ncbi.nlm.nih.gov/pubmed/35509452 http://dx.doi.org/10.2147/OTT.S215997 |
work_keys_str_mv | AT niedbałamarcin glioblastomapitfallsandopportunitiesofimmunotherapeuticcombinations AT malarzkatarzyna glioblastomapitfallsandopportunitiesofimmunotherapeuticcombinations AT sharmagitanjali glioblastomapitfallsandopportunitiesofimmunotherapeuticcombinations AT kramermarekgabriela glioblastomapitfallsandopportunitiesofimmunotherapeuticcombinations AT kasperawojciech glioblastomapitfallsandopportunitiesofimmunotherapeuticcombinations |